leisure time -WSS

leisure time

author：Wikipedia 2025-09-29 19:57:46 - browse：2

Daniel M. Skovronsky on stage at the 2023 STAT Summit. — Dan Skovronsky, Eli Lilly's chief scientific officer, at the 2023 STAT Summit. STAT

PHILADELPHIA — In a sense, the annual meeting of the American Heart Association wasn’t a huge one for Eli Lilly. Its biggest news was about a very early study of a drug to lower blood levels of Lp(a), a protein related to cholesterol that is mainly being watched by lipidologists and drug company analysts.

But in another way, the future of Lilly, now the biggest drug company by market capitalization, hung in the balance. Why? Because researchers were presenting data on the ability of Novo Nordisk’s obesity drug Wegovy to prevent heart attacks, strokes, and deaths in people with overweight who have established cardiovascular disease. That has big implications for the market for Lilly’s own obesity drug, Zepbound, which was approved by the Food and Drug Administration last week, and for the company’s future efforts in obesity.

STAT sat down with Lilly’s chief scientific officer, Dan Skovronsky, at the AHA meeting to talk about the obesity drugs known as GLP-1s, the new Lp(a) drug, and the company’s partnership with the gene editing firm Verve. An edited transcript of the conversation follows.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Heart attack and stroke risk calculators need revising

hotspot

WSS

The cancer drug shortage isn’t new — and neither are the solutions

Diverse clinical trials: Why aren’t we there yet?

New weight loss drugs vying to be the next Wegovy or Mounjaro

Will the IRA bring competition to the biologics market?

Food makers tried to stack nutrition panel with preferred experts

WATCH: Why do bright lights make us see spots?

leisure time

leisure time

Wikipedia

Alkermes shareholders re

White House touts steps to stem shortages of cancer treatments

In Memoriam: Notable people who died in 2023

After affirmative action ruling, medical educators look to 'holistic review'

Duchenne breakthrough therapy leaves behind pioneering families

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Diverse clinical trials: Why aren’t we there yet?

Medical leaders decry Supreme Court decision on affirmative action

Activists slam private health insurers over coverage restrictions

focus

Walmart eyes Medicare Advantage provider ChenMed

How medical schools plan to diversify without affirmative action

Diverse clinical trials: Why aren’t we there yet?

Apple is now the first public company to be valued at $3 trillion

In Memoriam: Notable people who died in 2023

Acelyrin, a rare IPO success, stumbles in its first big test

focus

focus

hotspot

focus